Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7542589,tmax ratio,"The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72.",Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542589/),,1.72,13916,DB06694,Xylometazoline
,26895496,terminal elimination half-life,"Following a single intravenous dose of antazoline mesylate (100 mg), the plasma concentration profile showed a relative fast elimination with a terminal elimination half-life of 2.29 h.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),h,2.29,154357,DB06694,Xylometazoline
,26895496,Vss,A relatively high volume of distribution was observed (Vss=315 L).,"Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),l,315,154358,DB06694,Xylometazoline
,26895496,mean residence time (MRT∞),"The values of mean residence time (MRT∞), area under the curve (AUC∞) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),h,3.45,154359,DB06694,Xylometazoline
,26895496,area under the curve (AUC∞),"The values of mean residence time (MRT∞), area under the curve (AUC∞) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[h·mg] / [l],0.91,154360,DB06694,Xylometazoline
,26895496,area under the curve (AUC∞),"The values of mean residence time (MRT∞), area under the curve (AUC∞) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[l] / [h],80.5,154361,DB06694,Xylometazoline
,26895496,clearance,"The values of mean residence time (MRT∞), area under the curve (AUC∞) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[l] / [h],80.5,154362,DB06694,Xylometazoline
